目前的潜在病原体的肌缩侧面硬化症
Shishi Jiang1,2, Renshi Xu3
1Department of Neurology, Jiangxi Provincial People's Hospital, Clinical College of Nanchang Medical College, First Affiliated Hospital of Nanchang Medical College, National Regional Center for Neurological Diseases, Xiangya Hospital of Center South University, Jiangxi Hospital. No. 152 of Aiguo Road, Donghu District, Nanchang, 330006, Jiangxi, China.
Molecular neurobiology
|June 3, 2024
概括
肌缩侧面硬化症 (ALS) 的发病原因尚不清楚,这阻碍了有效的治疗方法. 这篇评论探讨了基因变异和肠道微生物等关键因素,以寻找这种神经退行性疾病的新治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 微生物学 微生物学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病,其特征是运动神经元退化.
- 精确的ALS病原体尚未完全理解,缺乏有效的治疗方法.
- 关键的病理特征包括蛋白质聚合,遗传突变和神经炎症.
研究的目的:
- 系统地审查有关ALS潜在病原机制的当前研究.
- 要突出一些有前途的领域,如遗传变异,肠道失生症和细胞外囊泡运输.
- 为 ALS 开发新型治疗干预措施提供证据.
主要方法:
- 对最近关于ALS病变的研究进行系统文献综述.
- 分析研究的重点是遗传因素,肠道微生物组,质细胞激活和细胞外囊泡.
- 综合发现,以确定ALS发展中的关键途径.
主要成果:
- 遗传变异与家族性和零星性ALS有关.
- 肠道微生物失调症越来越被认为是导致的因素.
- 细胞外囊泡运输障碍和质细胞激活起着重要的作用.
结论:
- 了解遗传,微生物和细胞因素的复杂相互作用对于ALS至关重要.
- 针对这些途径可能会提供新的治疗途径.
- 对这些领域进行进一步的研究是有必要的,以开发有效的ALS治疗方法.
相关概念视频
Parkinson's Disease: Overview
527
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
527
Cross-bridge Cycle
117.3K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.3K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
575
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
575
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462


